Several reports suggest that there might be a preference for specific CTA re-expression in certain tumor types, exemplified by MAGEA1–4 in 70% of metastatic melanomas, ACRBP in 70% of ovarian tumors and NY-ESO-1 in 46% of breast tumors (7). Here, CTAG1B is linked to neoplasm.